In this interview, Theodoros Teknos, MD, discusses the results of his current phase I trial of vorinostat (Zolinza) in advanced head and neck cancer.
In this interview, Theodoros Teknos, MD, a Professor at The Ohio State University Medical School and Chairman for the Department of Otolaryngology (Head & Neck Surgery) at the Ohio State University Medical Center /James Cancer Hospital, sat down with the OncoTherapy Network to discuss the results of his current phase I trial of vorinostat (Zolinza) in advanced head and neck cancer.
These results were also presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 3-7, 2016, in Chicago (abstract 6036).
Pembrolizumab/Lenvatinib Combo Shows Mixed Results in Recurrent/Metastatic HNSCC
March 1st 2024Frontline pembrolizumab with or without chemotherapy appears to remain a standard of care for patients with recurrent or metastatic head and neck squamous cell carcinoma based on data from the LEAP-010 study.